NDAORALTABLET, EXTENDED RELEASE2 Generics Approved
Approved
Feb 2003
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Data completeness
3/8 — Basic
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDIZEM LA (diltiazem hydrochloride) is an extended-release calcium channel antagonist oral tablet approved for hypertension treatment. It works by inhibiting calcium ion influx during cardiac and vascular smooth muscle depolarization, reducing peripheral vascular resistance and lowering blood pressure. The drug produces antihypertensive effects without reflex tachycardia and maintains cardiac output through increased stroke volume.
$0.002BPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with modest spending and relatively low claim volume, suggesting team focus is on market maintenance rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CARDIZEM LA currently shows no linked job openings in pharmaceutical databases, reflecting its mature LOE status and modest commercial footprint relative to competitors. Working on this product offers limited growth trajectory but valuable experience in lifecycle management and market defense strategy within a competitive therapeutic class.
Company
Worked on CARDIZEM LA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.